New Published Data Highlights the Potential of Pluristem's PLX Cells in Improving Cardiac Function in Diabetes
October 16 2017 - 7:00AM
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) (TASE:PSTI) today
announced the publication of results from a preclinical study in
the peer-reviewed journal STEM CELLS Translational Medicine. The
article, titled “Placenta-derived adherent stromal cells improve
diabetes mellitus-associated left ventricular diastolic
performance”, highlights the ability of PLX cells to significantly
improve cardiac function and describes the underlying mechanism of
action. Results showed that treatment with PLX cells lead to
improved diastolic function by significantly decreasing
cardiomyocyte stiffness, endothelial inflammation, and improving
vascularization.
The study was performed by investigators from
the Berlin-Brandenburg Center for Regenerative Therapies, (BCRT)
and the Charité-Universitätsmedizin Berlin, Germany, led by
Professor Carsten Tschöpe. Dr. Tschöpe is also a member of
the Translational Research Committee of the Heart Failure
Association of the European Society of Cardiology.
In the study, diabetes mellitus was induced in
immune competent mice by streptozotocin application during 5
subsequent days. Seven days after the first streptozotocin
injection, animals were intravenously (IV) treated with either PLX
cells or saline (placebo). Cardiac parameters were assessed two
weeks later. The treatment using PLX cells led to improved
diastolic function as indicated by the heart-rate independent
1.2-fold (p<0.005) lower time constant of LV relaxation
parameter Tau and the 1.2-fold (p<0.05) increase of the
relaxation parameter dP/dtmin.
“Currently, there are limited treatment options
for diastolic dysfunction and even fewer for diabetes-induced
diastolic dysfunction," said Dr. Tschöpe. “This study holds promise
that PLX cells could potentially treat cardiac damage in diabetic
patients, particularly in early-stage diabetic cardiomyopathy. PLX
cells are particularly well suited for this indication because they
can be used without the need for tissue matching or
immunosuppression.”
“Diabetes-induced diastolic dysfunction is a
chronic disease that represents a large unmet need. In this study,
PLX cells were able to improve cardiac function when administered
by simple IV injection. This opens a potentially new method for an
effective, low risk treatment for diastolic dysfunction,” said Zami
Aberman, Chairman and Co-CEO of Pluristem. “These new data,
combined with findings published in the Journal of Surgical
Research, which showed that PLX cells were effective in treating
cardiac ischemia, suggest that PLX cells have the potential to
address a wide range of cardiac disorders.”
About Cardiac Diastolic
Dysfunction
Diastolic heart failure or diastolic dysfunction
refers to a decline in performance of one or both ventricles of the
heart during diastole, when the heart is filling with blood. The
National Heart, Lung, and Blood Institute reports that
approximately 4.8 million Americans suffer from heart failure, with
approximately 400,000 new cases appearing annually. Additionally,
it has been reported that 50% of these heart failure patients are
afflicted with diastolic heart failure (Curr Cardiol Rep, 2017).
Heart Failure with Preserved Ejection Fraction and Future
Pharmacological Strategies: a Glance in the Crystal Ball. Tschöpe
C, Van Linthout S, Kherad B. Curr Cardiol Rep. 2017
Aug;19(8):70
About Pluristem
Therapeutics
Pluristem Therapeutics Inc. is a leading
developer of placenta-based cell therapy products. The Company has
reported robust clinical trial data in multiple indications for its
patented PLX (PLacental eXpanded) cells, and is entering late-stage
trials in several indications. PLX cell products release a range of
therapeutic proteins in response to inflammation, ischemia, muscle
trauma, hematological disorders, and radiation damage. The cells
are grown using the Company's proprietary three-dimensional
expansion technology and can be administered to patients
off-the-shelf, without tissue matching. Pluristem has a strong
intellectual property position; Company-owned and operated,
GMP-certified manufacturing and research facilities; and strategic
relationships with major research institutions.
Safe Harbor Statement
This press release contains express or implied
forward-looking statements within the Private Securities Litigation
Reform Act of 1995 and other U.S. Federal securities laws. For
example, Pluristem is using forward-looking statements when its
discusses that the study holds promise that PLX cells may be able
to treat cardiac damage in diabetic patients, particularly at the
early stage of diabetic cardiomyopathy, that the study opens a
potentially new method for an effective, low risk treatment for
diastolic dysfunction and that the data derived from the study
suggest that PLX cells have the potential to address the wide range
of cardiac disorders. These forward-looking statements and their
implications are based on the current expectations of the
management of Pluristem only, and are subject to a number of
factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
The following factors, among others, could cause actual results to
differ materially from those described in the forward-looking
statements: changes in technology and market requirements;
Pluristem may encounter delays or obstacles in launching and/or
successfully completing its clinical trials; Pluristem’s products
may not be approved by regulatory agencies, Pluristem’s technology
may not be validated as it progresses further and its methods may
not be accepted by the scientific community; Pluristem may be
unable to retain or attract key employees whose knowledge is
essential to the development of its products; unforeseen scientific
difficulties may develop with Pluristem’s process; Pluristem’s
products may wind up being more expensive than it anticipates;
results in the laboratory may not translate to equally good results
in real clinical settings; results of preclinical studies may not
correlate with the results of human clinical trials; Pluristem’s
patents may not be sufficient; Pluristem’s products may harm
recipients; changes in legislation may adversely impact Pluristem;
inability to timely develop and introduce new technologies,
products and applications; loss of market share and pressure on
pricing resulting from competition, which could cause the actual
results or performance of Pluristem to differ materially from those
contemplated in such forward-looking statements. Except as
otherwise required by law, Pluristem undertakes no obligation to
publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. For a more detailed
description of the risks and uncertainties affecting Pluristem,
reference is made to Pluristem's reports filed from time to time
with the Securities and Exchange Commission.
Contact:
Karine Kleinhaus, MD, MPHDivisional VP, North
America1-914-512-4109karinek@pluristem.com
Efrat KaduriHead of Investor and Public
Relations972-74-7108600efratk@pluristem.com
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Sep 2023 to Sep 2024